50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Acute Myeloid Leukemia – Clinical Significance of Individual Molecular Markers

Monday, December 8, 2008: 7:00 AM-9:00 AM

Yerba Buena Ballroom Salon 9 (San Francisco Marriott)

Moderators:

Clara D. Bloomfield, MD and Stefan Frohling, MD

7:00 AM

Double, but Not Single, CEBPA mutations Define a Subgroup of Acute Myeloid Leukemia with Favorable Outcome and a Distinct Gene Expression Profile

Bas J. Wouters^*, Claudia A.J. Erpelinck-Verschueren^*, Bob Lowenberg, Peter J.M. Valk and Ruud Delwel

Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

7:15 AM

142

CEBPA Mutations Predict Favorable Prognosis in Pediatric AML

Phoenix Ho¹^*, Todd A. Alonzo², Robert B. Gerbing³^*, Jessica A. Pollard¹^*, Derek Stirewalt¹, Craig Alan Hurwitz⁴^*, Nyla A. Heerema⁵, Betsy Hirsch⁶^*, Susana C. Raimondi⁷, Beverly Lange⁸, Janet Franklin⁹, Jerald Radich¹ and Soheil Meshinchi¹

¹Fred Hutchinson Cancer Research Center, Seattle, WA
²Keck School of Med., Univ. of Southern California, Arcadia, CA
³Children's Oncology Group, Arcadia, CA
⁴The Maine Children's Cancer Program, Scarborough, ME
⁵Ohio State University, Columbus, OH
⁶Pathology, University of Minnesota, Minneapolis, MN
⁷St. Jude Children's Rsch. Hosp., Memphis, TN
⁸Oncology, Children's Hosp. of Philadelphia, Philadelphia, PA
⁹Children's Hospital Los Angeles, Los Angeles, CA

7:30 AM

143

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children's Oncology Group

Jessica A Pollard¹^*, Rong Zeng¹^*, Phoenix Ho¹^*, Todd Alonzo, PhD², Robert Gerbing³^*, Derek Stirewalt⁴, Nyla A. Heerema, PhD⁵, Susana C. Raimondi, PhD⁶, Betsy Hirsch⁷^*, Janet Franklin, MD, MPH⁸, Beverly Lange, MD⁹ and Soheil Meshinchi, MD, PhD¹

¹Clinical Research, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA
²Keck School of Med., Univ. of Southern California, Arcadia, CA
³Children's Oncology Group, Arcadia, CA
⁴Fred Hutchinson Cancer Research Ctr., Seattle, WA
⁵Ohio State University, Columbus, OH
⁶St. Jude Children's Rsch. Hosp., Memphis, TN
⁷Pathology, University of Minnesota, Minneapolis, MN
⁸Amgen Inc., Thousand Oaks, CA
⁹Oncology, Children's Hosp. of Philadelphia, Philadelphia, PA

7:45 AM

144

Wilms' Tumor 1 Gene Mutations in Childhood Acute Myeloid Leukemia: A New Prognostic factor with Implications for MRD Detection

Iris H.I.M. Hollink, MD¹^*, Marry M. van den Heuvel-Eibrink, MD, PhD¹^*, Martin Zimmermann, PhD²^*, Brian V. Balgobind, MD¹^*, Susan T.C.J.M. Arentsen-Peters¹^*, Mariel Alders, PhD³^*, Andre Willasch, MD, PhD⁴^*, Gertjan J.L. Kaspers, MD, PhD⁵, Jan Trka, MD, PhD⁶, Andre Baruchel, MD, PhD⁷, Siebold S.N. de Graaf, MD, PhD⁸^*, Ursula Creutzig⁹, Rob Pieters, MD, PhD¹, Dirk Reinhardt, MD, PhD² and C. Michel Zwaan, MD, PhD¹

¹Department of Pediatric Hematology/Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
²Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
³Clinical Genetics, Academic Medical Center, Amsterdam, Netherlands
⁴Hematology and Oncology, University Children's Hospital of Frankfurt, Frankfurt, Germany
⁵Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, Netherlands
⁶Pediatric Hematology and Oncology, 2nd Medical School, Charles University, Prague, Czech Republic
⁷Dept. of Pediatric Hematology, Hopital Saint Louis, Paris, France
⁸Dutch Childhood Oncology Group (DCOG), The Hague, Netherlands
⁹AML-BFM Study Group, University Children's Hospital, Münster, Germany

8:00 AM

145

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Verena I. Gaidzik, MD¹^*, Richard F. Schlenk, MD¹^*, Kerstin Wittke¹^*, Annegret Becker¹^*, Andreas Zimmermann¹^*, Brigitte Schlegelberger, MD², Arnold Ganser, MD, PhD³, Daniela Spaeth¹^*, Hartmut Doehner, MD¹^* and Konstanze Doehner, MD¹^*

¹Internal Medicine III, University of Ulm, Ulm, Germany
²Inst. of Cell & Molecular Pathology, Hannover, Germany
³Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

8:15 AM

146

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

Susanne Schnittger, PhD, Frank Dicker, PhD, Nicole Wendland^*, Tamara Weiss^*, Wolfgang Kern, MD, Torsten Haferlach, MD and Claudia Haferlach, MD

MLL Munich Leukemia Laboratory GmbH, Munich, Germany

8:30 AM

147

High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children's Oncology Group Study

Patrick Brown, MD¹, Todd Alonzo, PhD², Robert Gerbing³^*, Emily McIntyre¹^*, Beverly Lange, MD⁴, Donald Small¹^* and Soheil Meshinchi, MD, PhD⁵

¹Oncology and Pediatrics, Johns Hopkins University, Baltimore, MD
²Keck School of Med., Univ. of Southern California, Arcadia, CA
³Children's Oncology Group, Arcadia, CA
⁴Oncology, Children's Hosp. of Philadelphia, Philadelphia, PA
⁵Clinical Research, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA

8:45 AM

148

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

Jessica A Pollard¹^*, Todd Alonzo, PhD², Robert Gerbing³^*, Susana C. Raimondi, PhD⁴, Betsy Hirsch⁵^*, Janet Franklin, MD, MPH⁶, Alan Gamis, MD⁷, Michael R Loken⁸^* and Soheil Meshinchi, MD, PhD¹

¹Clinical Research, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA
²Keck School of Med., Univ. of Southern California, Arcadia, CA
³Children's Oncology Group, Arcadia, CA
⁴St. Jude Children's Rsch. Hosp., Memphis, TN
⁵Pathology, University of Minnesota, Minneapolis, MN
⁶Amgen Inc., Thousand Oaks, CA
⁷Children's Mercy Hospital, Kansas City, MO
⁸Hematologics, Inc, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

611.O1.8 Acute Myeloid Leukemia – Clinical Significance of Individual Molecular Markers